There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Urogen Pharma Ltd (URGN) and BeiGene Ltd (BGNE) with bullish sentiments.
Urogen Pharma Ltd (URGN)
In a report released today, Leland Gershell from Oppenheimer maintained a Buy rating on Urogen Pharma Ltd, with a price target of $70. The company’s shares opened today at $38.49, close to its 52-week low of $36.95.
Gershell wrote:
“URGN reported 4Q18 net loss of $23.7M vs. our $21.0M estimate. UGN-101’s rolling NDA submission is proceeding on track for a potential 1H20 launch in low-grade UTUC. We expect robust OLYMPUS data to drive approval, and project a $500M+ peak sales opportunity. Key 2019 newsflow to include initial reveal from UGN-102’s Phase 2 trial in NMIBC as well as data from BotuGel’s POC trial in OAB (w/AGN). YE18 cash of ~$260M pro forma for Jan. financing should provide over two years of runway. We see URGN as an attractive SMID-cap biotech pick.”
According to TipRanks.com, Gershell is a 2-star analyst with an average return of 0.3% and a 43.6% success rate. Gershell covers the Healthcare sector, focusing on stocks such as Evofem Biosciences Inc, AzurRx BioPharma Inc, and Catalyst Pharma.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Urogen Pharma Ltd with a $72.67 average price target.
See today’s analyst top recommended stocks >>
BeiGene Ltd (BGNE)
Maxim Group analyst Jason McCarthy maintained a Buy rating on BeiGene Ltd today and set a price target of $170. The company’s shares opened today at $135.01.
McCarthy observed:
“BeiGene reported 4Q18 earnings with revenue of $58.7M vs. consensus of $66.5M. Total product sales derived from Celgene (CELG – NR) partnered products, China were relatively flat ($37.8.M vs. $38.5.M in 3Q18) due to seasonal patterns that is typical of fourth quarter sales in China. Net loss for the quarter was ($268M) and the company ended the period with $1.8B in cash.”
According to TipRanks.com, McCarthy has currently no stars on a ranking scale of 0-5 stars, with an average return of -2.5% and a 33.4% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Aridis Pharmaceuticals Inc, and Adial Pharmaceuticals Inc.
BeiGene Ltd has an analyst consensus of Strong Buy, with a price target consensus of $180, which is a 33.3% upside from current levels. In a report issued on February 25, Cowen & Co. also maintained a Buy rating on the stock with a $170 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
